Management of post-transplant lymphoproliferative disorders

Christin B. DeStefano*, Sanjal H. Desai, Aarthi G. Shenoy, Joseph P. Catlett

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations

Abstract

The post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone marrow and solid organ transplants. Because these disorders are rare, there are no randomized trials from which to derive optimal treatment. Management can be challenging and must balance the goal of PTLD eradication with the risks of graft rejection, graft-versus-host disease, further delays in immune reconstitution and life-threatening infections, among others. This paper will provide a comprehensive review of PTLD following solid organ transplant and haematopoietic stem cell transplant with a focus on management. Included is a discussion of novel agents that are being studied in clinical trials and, when combined or sequenced with conventional therapy, have the potential to improve outcomes.

Original languageEnglish
Pages (from-to)330-343
Number of pages14
JournalBritish Journal of Haematology
Volume182
Issue number3
DOIs
StatePublished - Aug 2018
Externally publishedYes

Keywords

  • cellular therapies
  • Epstein-Barr virus
  • lymphoproliferative disease
  • new drugs for lymphoma
  • transplantation

Fingerprint

Dive into the research topics of 'Management of post-transplant lymphoproliferative disorders'. Together they form a unique fingerprint.

Cite this